PubRank

S R Burrows

Author PubWeight™ 75.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992 3.75
2 Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 1988 2.85
3 Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med 1994 2.47
4 Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000 2.17
5 Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995 1.90
6 Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999 1.82
7 Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008 1.77
8 Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A 1990 1.74
9 Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995 1.62
10 HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 1998 1.58
11 Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998 1.51
12 Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol 1997 1.34
13 Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology 1991 1.30
14 Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol 2001 1.27
15 Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 1995 1.27
16 Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol 1996 1.27
17 Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol 1997 1.25
18 Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A 1991 1.20
19 T lymphocytes in infectious mononucleosis. I. T cell death in vitro. Clin Exp Immunol 1985 1.17
20 Immune surveillance against Epstein-Barr virus. Semin Immunol 1992 1.16
21 X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol 1999 1.15
22 Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J Exp Med 1996 1.15
23 Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A 1995 1.14
24 A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 2001 1.14
25 A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer 1983 1.13
26 Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998 1.10
27 Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood 2001 1.09
28 T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J Exp Med 1991 1.08
29 The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 2001 1.04
30 Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int Immunol 1997 1.00
31 Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J Virol 1996 0.99
32 Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J Biol Chem 2001 0.99
33 Distinct functions of tapasin revealed by polymorphism in MHC class I peptide loading. J Immunol 2000 0.99
34 Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis. Springer Semin Immunopathol 1991 0.99
35 Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996 0.97
36 Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999 0.96
37 Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J Immunol Methods 1993 0.95
38 T lymphocytes in infectious mononucleosis. II. Response in vitro to interleukin-2 and establishment of T cell lines. Clin Exp Immunol 1985 0.93
39 Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol 1994 0.93
40 Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int J Cancer 1983 0.93
41 A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997 0.92
42 Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997 0.92
43 Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Eur J Immunol 1999 0.91
44 Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011 0.91
45 Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines. J Virol 1997 0.90
46 Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol 1998 0.90
47 High frequency of herpesvirus-specific clonotypes in the human T cell repertoire can remain stable over decades with minimal turnover. J Virol 2012 0.89
48 Calcium concentration defines two stages in transformation of lymphocytes by Epstein-Barr virus. Int J Cancer 1984 0.87
49 Strains of Epstein-Barr virus infecting multiple sclerosis patients. Mult Scler 2010 0.86
50 Interleukin-1 beta-converting enzyme-like protease cleaves DNA-dependent protein kinase in cytotoxic T cell killing. J Exp Med 1996 0.86
51 EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 1999 0.86
52 EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J Immunol 1993 0.86
53 The Aspergillus nidulans xprF gene encodes a hexokinase-like protein involved in the regulation of extracellular proteases. Genetics 2000 0.85
54 BLT esterase activity as an alternative to chromium release in cytotoxic T cell assays. J Immunol Methods 1991 0.84
55 Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in EBNA 3. J Gen Virol 1991 0.83
56 Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response. Ciba Found Symp 1994 0.83
57 Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen. Clin Exp Immunol 1992 0.82
58 Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. Implications for peripheral T cell deletion and peptide vaccination. J Immunol 1993 0.80
59 The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses. Trends Microbiol 1997 0.79
60 Differential splicing of antigen-encoding RNA reduces endogenous epitope presentation that regulates the expansion and cytotoxicity of T cells. J Immunol 2000 0.79
61 Interleukin-2 receptors in infectious mononucleosis. Immunol Lett 1989 0.78
62 Expression of p53, bcl-2, bax, bcl-x2 and c-myc in radiation-induced apoptosis in Burkitt's lymphoma cells. Cell Death Differ 1996 0.77
63 Epstein-Barr virus-specific cytotoxic T cell response in cardiac transplant recipients. Transplantation 1994 0.77
64 Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants. J Virol 1996 0.77
65 Oligopeptide induction of a secondary cytotoxic T-cell response to Epstein-Barr virus in vitro. Scand J Immunol 1991 0.77
66 Modification of the carboxyl terminal group affects replacement set analysis of a cytotoxic T cell epitope. Pept Res 1996 0.75
67 T lymphocytes in infectious mononucleosis; effect of IL-2 on the outgrowth of Epstein-Barr virus-infected cells. Immunol Cell Biol 1989 0.75
68 Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies. J Acquir Immune Defic Syndr 1999 0.75
69 Inhibition of HLA B8-restricted recognition by unrelated peptides: evidence for allosteric inhibition. Immunol Lett 1991 0.75